Cell Substrates

1. Front Matter

   Pages i-viii

   PDF

2. Past Achievements — Future Expectations

   1. Past Achievements — Future Expectations

      • Harry M. Meyer Jr.

      Pages 1-5

3. Cell Substrates: General Overview

   1. Introductory Remarks

      • Saul Krugman

      Pages 7-7

   2. Cell Substrates for Biologics Production: Factors Affecting Acceptability

      • John C. Petricciani

      Pages 9-21

   3. Quantitation in the Evaluation of Cell Substrates for Viral Vaccine Production

      • Wade P. Parks, Elizabeth S. Hubbell

      Pages 23-33

   4. Human Cells and the Finite Lifespan Theory

      • Thomas B. L. Kirkwood, Robin Holliday

      Pages 35-46

   5. Line Cell Saga — An Argument in Favor of Production of Biologics in Cancer Cells

      • Maurice R. Hilleman

      Pages 47-58

4. Viral Vaccine Substrates

   1. Introductory Remarks

      • John P. Fox

      Pages 59-60

   2. Viral Vaccines under Development: A Third Generation

      • June E. Osborn

      Pages 61-82

   3. Choice of Cell Substrate for Biological Products

      • A. J. Beale

      Pages 83-97

   4. Recommendations for Inactivated Human Vaccines Produced on Human Diploid Cells

      • Robert Netter

      Pages 99-106

   5. The Spector of Malignancy and Criteria for Cell Lines as Substrates for Vaccines

      • Jonas Salk

      Pages 107-113

5. Cell Substrates for Biologicals other than Vaccines

   1. Introductory Remarks

      • Jan Vilček

      Pages 115-116

   2. Interferon as a Cell Product

      • Jan Vilcek

      Pages 117-127

   3. Urokinase as a Cell Product

      • Joseph C. Fratantoni

      Pages 129-133

   4. Production of Biologicals by Plant Cell Cultures

      • Donald K. Dougall

      Pages 135-152

   5. Use of Recombinant DNA Technology for the Production of Polypeptides

      • Walter L. Miller

      Pages 153-174

   6. Molecular Biology and Public Health

      • Robert R. Wagner

      Pages 175-183

6. Summary and Considerations for the Future

   1. Introductory Remarks

      • Thomas C. Merigan

      Pages 185-185

   2. Benefit-Risk Assessment

      • H. Bruce Dull

      Pages 187-193

This volume stems from a symposium sponsored by the W. Alton Jones Cell Science Center, Lake Placid New York. The Second Annual W. Alton Jones Cell Science Center Symposium: Cell Substrates and­ Their Use in the Production of Vaccines and Other Biologicals was held October 23-26, 1978. The Center is an operational unit of the Tissue Culture Association and offers, in collaboration with the Association's Education Committee, a wide range of educational and research activities. During the past 20 years there have been numerous national and international conferences on the topic of cell cultures used to produce biological products. Those largely dealt with the technology and associated issues that were current at the time of the meetings. For example, as human diploid cells were developed and proposed for use in vaccine production, a number of meetings were held to examine the pros and cons of human diploid cells. A large amount of data was provided at those conferences which formed the basis for the eventual acceptance of that cell system. Each meeting added to the general base of knowledge in the area of cell cultures and their application to the current and novel set of problems encountered. In general, the participants reaffirmed the basic premises that were formulated in the early days of polio virus vaccine production regarding the criteria for acceptability of cells when used in the manufacture of biologics intended for humans.

• cell
• cell culture
• research
• tissue
• vaccine

• Bureau of Biologics of the Food and Drug Administration, Bethesda, USA

  John C. Petricciani, Hope E. Hopps

• W. Alton Jones Cell Science Center, Lake Placid, USA

  Paul J. Chapple

Policies and ethics